Primary cutaneous CD4+ small/medium T-cell lymphoma with aggressive clinical course

2014 ◽  
Vol 55 (4) ◽  
pp. 304-306 ◽  
Author(s):  
Masahito Yasuda ◽  
Naoya Igarashi ◽  
Yayoi Nagai ◽  
Atsushi Tamura ◽  
Osamu Ishikawa
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Aggressive Clinical Course

Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.

1987 ◽  
Vol 5 (2) ◽  
pp. 208-215 ◽  
Author(s):  
E Dmitrovsky ◽  
M J Matthews ◽  
P A Bunn ◽  
G P Schechter ◽  
R W Makuch ◽  
...  
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Large Cell ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Blood Smears ◽  
Large Cell Lymphoma ◽  
Aggressive Clinical Course ◽  
Peripheral Blood Smears

The clinical course of cutaneous T cell lymphoma (mycosis fungoides and Sezary syndrome) is generally indolent, but in occasional patients becomes fulminant. We found that biopsies from patients with accelerating disease can reveal cytologic transformation from previously observed small, convoluted lymphocytes to large cells that are similar to cells seen in large-cell lymphoma. The cerebriform nuclei characteristic of malignant T cells can only rarely be identified. Of 150 cutaneous T cell lymphoma patients we treated from 1976 to 1984, cytologic transformation was identified in 12 after review of peripheral blood smears and biopsies from skin, lymph nodes, and visceral sites. Patients who developed cytologic transformation were initially characterized by advanced stage (11 of 12), with lymph node effacement (seven of 11) and erythroderma (five of 12). The tumor cell DNA content after transformation was aneuploid (four of four), and the ability to form rosettes with sheep erythrocytes was retained in transformed cells (three of three). The median time from diagnosis of cutaneous T cell lymphoma to cytologic transformation was 21.5 months (range, 4 to 64), and the median survival from transformation was only 2 months (range, 0 to 19+). We conclude that cytologic transformation in cutaneous T cell lymphoma represents a distinct clinicopathologic entity, characterized by an aggressive clinical course.

PP - PRIMARY CUTANEOUS CD8+ T-CELL LYMPHOMA: A CASE REPORT WITH UNUSUAL FACIAL INVOLVEMENT AND AN AGGRESSIVE CLINICAL COURSE

2017 ◽  
Vol 123 (2) ◽  
pp. e56
Author(s):  
DAPHINE CAXIAS TRAVASSOS ◽  
DARCY FERNANDES ◽  
ELAINE MARIA SGAVIOLI MASSUCATO ◽  
CLAUDIA MARIA NAVARRO ◽  
MIRIAN APARECIDA ONOFRE ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Cd8 T Cell ◽  
T Cell Lymphoma ◽  
Aggressive Clinical Course

scholarly journals THERAPY OF THE RESISTANT FORMS OF SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA

2019 ◽  
Vol 64 (3) ◽  
pp. 353-361
Author(s):  
L. G. Gorenkova ◽  
S. K. Kravchenko ◽  
M. A. Silaev ◽  
N. V. Ryzhikova
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Case Reports ◽  
Clinical Manifestations ◽  
Lymphoproliferative Disorders ◽  
T Cell Lymphoma ◽  
Aggressive Clinical Course ◽  
Rare Group

Introduction. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) belongs to a rare group of skin lymphoproliferative disorders, which is characterised by panniculitis-like clinical manifestations, the α/β cytotoxic immunophenotype of tumour cells, as well as a multidirectional course from indolent to aggressive forms.Aim. To examine patients with SPTCL having an aggressive clinical course and characterised by refractoriness to several lines of chemotherapy.Results. We present two case reports of patients with a generalised lesions and unfavourable prognostic factors, who achieved complete long-term remission of the disease as a result of gemcitabine chemotherapy.Conclusion. Despite the fact that both observed SPTCL patients demonstrated refractoriness to at least three types of treatment, the use of gemcitabine allowed long-term complete remissions of the disease to be achieved. 

scholarly journals NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021

2020 ◽  
Vol 18 (11) ◽  
pp. 1460-1467
Author(s):  
Steven M. Horwitz ◽  
Stephen Ansell ◽  
Weiyun Z. Ai ◽  
Jeffrey Barnes ◽  
Stefan K. Barta ◽  
...  
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
T Cell Lymphoma ◽  
Nccn Guidelines ◽  
T Cell Lymphomas ◽  
Hepatosplenic T Cell Lymphoma ◽  
Aggressive Clinical Course ◽  
Worse Prognosis

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Clinical Course of Retrovirus-Associated Adult T-Cell Lymphoma in the United States

1983 ◽  
Vol 309 (5) ◽  
pp. 257-264 ◽  
Author(s):  
Paul A. Bunn ◽  
Geraldine P. Schechter ◽  
Elaine Jaffe ◽  
Douglas Blayney ◽  
Robert C. Young ◽  
...  
Keyword(s):  
United States ◽  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
The United States ◽  
T Cell Lymphoma

scholarly journals Distinct morphologic, phenotypic, and clinical-course characteristics of indolent peripheral T-cell lymphoma

2013 ◽  
Vol 44 (9) ◽  
pp. 1927-1936 ◽  
Author(s):  
Eiko Hayashi ◽  
Katsuyoshi Takata ◽  
Yasuharu Sato ◽  
Yukie Tashiro ◽  
Yoshiro Tachiyama ◽  
...  
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Peripheral T Cell Lymphoma ◽  
Course Characteristics

scholarly journals NK/T-cell lymphoma nasal type with an unusual clinical course

2014 ◽  
Vol 80 (6) ◽  
pp. 564 ◽  
Author(s):  
Vladimira Radochova ◽  
Jakub Radocha ◽  
Marketa Nova ◽  
David Belada ◽  
Radovan Slezak
Keyword(s):  
T Cell ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Nk T Cell

Clinicopathological Characteristics and Clinical Course of CD8 Expressing Primary Cutaneous Peripheral T-Cell Lymphomas (CTCL) - Retrospective Case Study

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5213-5213
Author(s):  
Deniz Peker ◽  
Yizhou Zhang ◽  
Young Yu ◽  
Zhigang Zhao ◽  
Yafei Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
T Cell ◽  
Clinical Outcome ◽  
Clinical Course ◽  
Cell Lymphoma ◽  
Clinicopathological Characteristics ◽  
Therapeutic Strategies ◽  
T Cell Lymphoma ◽  
T Cell Lymphomas

Abstract Abstract 5213 Background: CD8-positive primary cutaneous T cell lymphomas (CTCL) are rare disorders and mainly include primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (AECTL) and CD8+ variant mycosis fungoides (MF). In contrast to primary cutaneous CD8+ AECTL, which frequently exhibits strikingly aggressive and unfavorable clinical behavior, CD8+ MF shows debatable clinical course, from an indolent to aggressive behavior. As previously reported, the indolent subtype CD8+ MF occur more frequently in pediatric group, while both clinical subtypes have been observed in adults. Albeit single case studies or small case series have been reported in the literature, it still lacks a large scale of study to enlighten the clinicopathological aspects of CD8+ primary CTCLs, in order to develop the appropriate therapeutic strategies. This study aims to retrospectively review these two entities to demonstrate their clinicopathologic characteristics and to correlate them with the clinical outcome. Design: The hematopathology files from H. Lee Moffitt Cancer Center & Research Institute (PATHNET) and Tianjian Cancer Research Institute were retrieved. The patients with a primary diagnosis of CD8 expressing primary CTCLs, diagnosed and treated between January 2004 and June 2011, were included. Cutaneous involvement by systemic peripheral T-cell lymphoma, primary cutanous gamma delta T-cell lymphoma, and subcutaneous panniculitis-like T-cell lymphoma were excluded. The corresponding patient demographics, laboratory datas, therapeutic strategies and the clinical outcomes were reviewed. All available histology slides, along with all of the ancillary study results were reviewed and correlated with the clinical outcome. Results: Total of 10 cases were included based on the confirmed histomorphological diagnosis. Cases were divided into two groups: 1) CD8+ MF (n=5) and 2) CD8+ non-MF (n=5) including 2 cases with definitive diagnosis of AECTL and 3 cases diagnosed as CD8-positive primary cutaneous T cell lymphoma, not further classifiable. Clinicopathological characteristics including patients' demographic data, diagnosis, site of involvement, treatment, duration of follow up and clinical outcomes are summarized in table 1. The overall survival time for CD8+CTCLs, non-MF type (excluding 1 patient with lost follow up) varied from 5 to 90 months (averaging 20.5 months) while it was shorter in CD8+ MF, 12.6 months (5 to 23 months). Of note, 1 patient with AECTL expired shortly after diagnosis, within 3 months, however; the other one received allogeneic hematopoietic stem cell transplant (allo-HSCT) and has been alive up to date. Conclusion: CD8-positive CTCLs remain a diagnostic challenge. CD8+ MF in adults exhibit dual growth patterns: localized or systemically disseminated disease. The latter could have a very short median overall survival regardless of the aggressive therapies. Allo-HSCT might be beneficial to those with AECTL. Larger series of CD8+ MF should be investigated for molecular gene profiling in order to establish genetic, molecular and phenotypic parameters not only to separate the indolent form from the aggressive subtype, but also to distinguish it from primary cutaneous CD8-positive AECTL. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document